Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study

By sjmartinez • July 19, 2023

Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S. Oral spleen tyrosine kinase/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: Results of a randomized phase 2 study. J Am Acad Dermatol. 2023 Aug;89(2):235-242. doi: 10.1016/j.jaad.2023.04.027. Epub 2023 Apr 23. PMID: 37094653.

Tags: Chronic Hand Eczema, Dermatology, Janus kinase inhibitor, modified total lesion-symptom score, Olive View DoM, Physician Global Assessment, Publications, Spleen Kinase Inhibitor

Increased mitochondrial mutation heteroplasmy induces aging phenotypes in pluripotent stem cells and their differentiated progeny

Vandiver AR, Torres A Jr, Sanden A, Nguyen TL, Gasilla J, Doan MT, Martirosian V, Hoang A, Wanagat J, Teitell MA. Increased mitochondrial mutation heteroplasmy[...]

Update on Absorbable Facial Thread Lifts

Riopelle AM, Geisler AN, Eber A, Dover JS. Update on Absorbable Facial Thread Lifts. Dermatol Surg. 2024 Dec 11. doi: 10.1097/DSS.0000000000004521. Epub ahead of print.[...]

Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma

Dong E, Yashar S, Mandelkern M, Kaunitz J. Unusual Cutaneous Metastasis in a Patient with Cholangiocarcinoma. Dig Dis Sci. 2024 Dec 11. doi: 10.1007/s10620-024-08775-1. Epub[...]